

Capital Markets

2024

2024: Market leaders and major investment banks turn to WilmerHale for capital markets legal advice and business advantage. In 2023, we handled more than 60 public offerings, Rule 144A placements, PIPE financings, and other equity and debt capital markets transactions, raising in excess of \$35 billion for leading companies in life sciences, technology, financial services and various other industries. Since 2013, we have served as counsel in over 600 capital markets transactions with total proceeds of approximately \$300 billion. In addition, our capital markets lawyers routinely advise clients on a wide variety of debt financing transactions, including term loans, working capital facilities, acquisition financing, liability management transactions and recapitalizations. We have one of the leading IPO practices in the United States—as both issuer counsel and underwriters’ counsel—with particular experience in IPOs by high-growth, entrepreneurial companies in a range of life sciences and technology sectors. The following is a selection of our recent capital markets transactions.



WILMER CUTLER PICKERING HALE AND DORR LLP

Counsel of Choice for Capital Markets Transactions

Serving market leaders in technology, life sciences, financial services and a wide variety of other industries

<p>S&P Global</p> <p>Exchange Offer \$7,049,783,000 March 2023</p> <p>Rule 144A Placement of Senior Notes \$750,000,000 September 2023 Counsel to Issuer</p>	<p>ANALOG DEVICES</p> <p>Public Offering of Senior Notes \$300,000,000 September 2022</p> <p>Exchange Offer \$427,480,000 September 2023 Counsel to Issuer</p>	<p>ThermoFisher SCIENTIFIC</p> <p>Public Offerings of Senior Notes €1,250,000,000 \$1,200,000,000 November 2022</p> <p>\$5,450,000,000 August and December 2023 Counsel to Issuer</p>	<p>Veralto</p> <p>Rule 144A/Regulation S Private Placements of Senior Notes \$2,100,000,000 €500,000,000 September 2023 Counsel to Issuer</p>	<p>STATE STREET</p> <p>Public Offerings of Senior Notes \$10,000,000,000 February, May, August, November 2022 and January, May, August, November 2023 Counsel to Issuer</p>	<p>Medtronic</p> <p>Public Offerings of Senior Notes €3,500,000,000 September 2022</p> <p>\$2,000,000,000 March 2023 Counsel to Issuer</p>	<p>Akamai</p> <p>Rule 144A Placement of Senior Notes \$1,265,000,000 August 2023 Counsel to Issuer</p>	<p>DTCC</p> <p>Rule 144A Placement of Senior Notes \$1,000,000,000 May 2023 Counsel to Issuer</p>	<p>casella</p> <p>Public Offering of Common Stock \$517,500,000 June 2023 Counsel to Issuer</p>
<p>EASTMAN</p> <p>Public Offerings of Senior Notes \$500,000,000 Green Bond March 2023</p> <p>\$750,000,000 February 2024 Counsel to Issuer</p>	<p>mc</p> <p>Public Offering of Senior Notes \$500,000,000 April 2023 Counsel to Issuer</p>	<p>Nuvalent</p> <p>Public Offerings of Common Stock \$264,500,000 November 2022</p> <p>\$345,000,000 October 2023 Counsel to Issuer</p>	<p>mks Technology for Productivity</p> <p>Public Offering of Common Stock by Selling Stockholders \$193,520,000 June 2023 Counsel to Issuer</p>	<p>disc)medicine</p> <p>Public Offering of Common Stock and Pre-Funded Warrants \$157,780,000 June 2023 Counsel to Underwriters</p>	<p>Avadel</p> <p>Public Offering of Ordinary Shares and Non-Voting Convertible Preferred Shares \$143,750,000 April 2023</p> <p>Exchange Offer \$106,268,000 April 2023 Counsel to Underwriters</p>	<p>editas MEDICINE</p> <p>Public Offering of Common Stock \$125,000,000 June 2023 Counsel to Issuer</p>	<p>astria THERAPEUTICS</p> <p>Public Offering of Common Stock, Common Stock Warrants and Pre-Funded Warrants \$63,998,500 October 2023</p> <p>Public Offering of Common Stock \$125,010,500 February 2024 Counsel to Issuer</p>	
<p>inozyme pharma</p> <p>Public Offering of Common Stock and Pre-Funded Warrants \$73,061,500 April 2022</p> <p>Public Offering of Common Stock \$69,000,000 August 2023 Counsel to Issuer</p>	<p>ikena ONCOLOGY</p> <p>Public Offering of Common Stock \$40,020,500 May 2023 Counsel to Underwriters</p>	<p>verve THERAPEUTICS</p> <p>Public Offerings of Common Stock \$258,750,000 July 2022</p> <p>\$143,750,000 December 2023 Counsel to Issuer</p>	<p>Celldex therapeutics</p> <p>Public Offerings of Common Stock \$230,546,000 November 2023</p> <p>\$460,506,000 March 2024 Counsel to Underwriters</p>	<p>Ocular Therapeutix</p> <p>Public Offering of Common Stock \$115,115,000 December 2023</p> <p>PIPE Placement of Common Stock and Pre-Funded Warrants \$325,000,000 February 2024 Counsel to Issuer</p>	<p>dynatrace</p> <p>Public Offerings of Common Stock by Selling Stockholders \$1,252,250,000 February and November 2023 Counsel to Underwriters</p>	<p>Apellis</p> <p>Public Offering of Common Stock \$402,500,000 March 2022</p> <p>Public Offering of Common Stock and Pre-Funded Warrants \$402,500,000 February 2023 Counsel to Issuer</p>	<p>SYROS</p> <p>Public Offering of Common Stock and Pre-Funded Warrants \$45,000,000 December 2023 Counsel to Issuer</p>	<p>VIRIDIAN</p> <p>Public Offering of Common Stock and Preferred Stock \$310,787,500 August 2022</p> <p>Public Offering of Common Stock \$150,000,000 January 2024 Counsel to Underwriters</p>
<p>voyager therapeutics</p> <p>Public Offering of Common Stock and Pre-Funded Warrants \$99,996,500 January 2024 Counsel to Issuer</p>	<p>CINCOR</p> <p>Initial Public Offering of Common Stock \$212,653,000 January 2022</p> <p>Public Offering of Common Stock and Pre-Funded Warrants \$258,750,000 August 2022 Counsel to Underwriters</p>	<p>AMYLYX</p> <p>Initial Public Offering of Common Stock \$216,018,000 January 2022</p> <p>Public Offering of Common Stock \$246,330,000 October 2022 Counsel to Underwriters</p>	<p>Dyne THERAPEUTICS</p> <p>Public Offering of Common Stock \$345,143,750 January 2024 Counsel to Issuer</p>	<p>ARCELLX</p> <p>Initial Public Offering of Common Stock \$142,312,500 February 2022</p> <p>Public Offering of Common Stock \$128,800,000 June 2022 Counsel to Underwriters</p>	<p>ARVINAS</p> <p>PIPE Placement of Common Stock and Pre-Funded Warrants \$350,000,000 November 2023 Counsel to Issuer</p>	<p>KYMERA</p> <p>Public Offering of Common Stock and Pre-Funded Warrants \$316,249,000 January 2024 Counsel to Underwriters</p>	<p>SOLID BIOSCIENCES</p> <p>PIPE Placement of Common Stock \$75,000,000 December 2022</p> <p>PIPE Placement of Common Stock and Pre-Funded Warrants \$108,858,550 January 2024 Counsel to Issuer</p>	

Connect with us   

[wilmerhale.com](https://www.wilmerhale.com)

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 2100 Pennsylvania Avenue NW, Washington, DC 20037, +1 202 663 6000. Our United Kingdom office is operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK office. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2024 Wilmer Cutler Pickering Hale and Dorr LLP